How GLP-1 Drugs Like Ozempic Actually Cause Weight Loss Through Brain and Body

GLP-1 receptor agonists have emerged as game-changing weight loss medications, with drugs like semaglutide achieving 15-20% body weight reduction in clinical trials. However, the precise mechanisms driving these dramatic results have needed clearer explanation for clinicians and patients.

This comprehensive review by researchers from McGill University systematically examines both central and peripheral pathways through which GLP-1 receptor agonists induce weight loss. The authors analyze how these medications work in the brain to suppress appetite and regulate satiety, while simultaneously affecting peripheral tissues to alter metabolism and energy balance.

Central mechanisms likely include direct effects on hypothalamic appetite centers, enhanced satiety signaling, and reduced food reward pathways. Peripheral actions encompass delayed gastric emptying, improved insulin sensitivity, altered gut hormone release, and potential effects on energy expenditure through brown adipose tissue activation.

The dual-pathway approach explains why GLP-1 drugs outperform previous weight loss medications that targeted single mechanisms. This mechanistic understanding could inform dosing strategies, combination therapies, and patient selection. For clinicians, recognizing both central and peripheral effects helps explain the medications' comprehensive metabolic benefits beyond weight loss, including improved glycemic control and cardiovascular outcomes. The review provides crucial insights for optimizing GLP-1 therapy in clinical practice and understanding why these drugs represent a paradigm shift in obesity treatment.